The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies.
The effect of BM 12.531 (BM) treatment on normal or tumored mice was studied under both in vitro and in vivo experimental conditions. It was found that BM treatment of mice that received 500 R of whole body irradiation caused a highly significant (P < 0.001) increase in the prolongation of the mean survival time. BM was found to significantly increase (P < 0.01) the delayed-type hypersensitivity reaction of normal mice. BM treatment was found to moderately increase both in vivo and in vitro activated macrophages. However, BM was found to be extremely effective in significantly increasing the mean survival times of lung carcinoma-bearing or leukemic mice.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D001388:Aziridines / Q000276:immunology / Q000494:pharmacology*; D001389:Azirines / Q000494:pharmacology*; D002478:Cells, Cultured; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007111:Immunity, Cellular / Q000187:drug effects*; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014965:X-Rays
D001388:Aziridines; D001389:Azirines; C016866:azimexon